Email this article Comparison of the effectiveness of rabeprazole original and generic products in the monotherapy of gastroesophageal reflux disease
- Authors: Krapivnaia O.V.1,2
-
Affiliations:
- Khabarovsk Clinical Hospital “RZD-Medicine”
- Far East State Medical University
- Issue: Vol 95, No 8 (2023)
- Pages: 670-673
- Section: Original articles
- URL: https://journal-vniispk.ru/0040-3660/article/view/148314
- DOI: https://doi.org/10.26442/00403660.2023.08.202346
- ID: 148314
Cite item
Full Text
Abstract
Aim. To compare the effectiveness of rabeprazole original and generic products in the treatment of gastroesophageal reflux disease (GERD) using impedance-pH monitoring.
Materials and methods. Patients (n=35) diagnosed with GERD were divided into two groups. Group 1 patients (n=17, 45.2±1.7 years) received the rabeprazole original product (Pariet) 20 mg/day; Group 2 patients (n=18, 48.1±1.9 years) received 20 mg/day of a generic product. On Day 10 of therapy, all patients underwent 24-hour esophagus impedance-pH monitoring (Ohmega, Medical Measurement Systems, the Netherlands). The percentage of time with pH<4 in the esophagus, the total number and number of acidic, slightly acidic and slightly alkaline gastroesophageal refluxes (GERs), the latency period, and the duration of rabeprazole action were analyzed. The clinical efficacy of the drug was assessed using the GerdQ questionnaire. Statistical data were processed using Microsoft Office 2010 (Excel) and Biostat 2000 software packages.
Results. No significant differences were noted between the two groups of patients by gender, age, body mass index, smoking frequency, and GERD type (p>0.05). The average duration of action of the rabeprazole original product was significantly higher than that of the generics (13.2±0.6 and 8.8±0.7 h, respectively, p<0.05). In the rabeprazole original product group, compared to the generics group, the following values were lower: total GERs – 47.0 [43.3; 60.0] and 71.8 [54.3; 95.0], respectively, p<0.05; percentage of time with intraesophageal pH<4 – 1.8 [0.5; 2.3] and 2.1 [0.3; 6.8], respectively, p<0.05; the number of acidic GERs – 4.7 [2.2; 12.0] and 23.3 [12.6; 32.0], respectively, p<0.05. The total GerdQ questionnaire score in Group 1 was significantly lower than in Group 2 (5.4±0.1 vs 6.9±0.4, respectively; p>0.05).
Conclusion. In treating GERD with the rabeprazole original product compared to generics, a significantly longer duration of acid production suppression, a more pronounced decrease in esophageal acidification, and a more statistically significant clinical improvement were observed.
Full Text
##article.viewOnOriginalSite##About the authors
Oksana V. Krapivnaia
Khabarovsk Clinical Hospital “RZD-Medicine”; Far East State Medical University
Author for correspondence.
Email: ovkrapivnaya@gmail.com
ORCID iD: 0000-0002-5912-3166
д-р мед. наук, зав. гастроэнтерологическим отд-нием ЧУЗ «КБ "РЖД-Медицина" г. Хабаровск», доц. каф. госпитальной терапии ФГБОУ ВО ДВГМУ
Russian Federation, Khabarovsk; KhabarovskReferences
- Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97 (in Russian)]. doi: 10.22416/1382-4376-2020-30-4-70-97
- Лопина О.Д., Нургалиева Б.К., Лапина Т.Л. Актуальные тенденции в лечении кислотозависимых заболеваний: клиническая эффективность и безопасность рабепразола. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):55-63 [Lopina OD, Nurgalieva BK, Lapina TL. Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):55-63 (in Russian)]. doi: 10.22416/1382-4376-2021-31-4-55-63
- Трухманов А.С., Сторонова О.А., Ивашкин В.Т. Клиническое значение 24-часовой pH-метрии в диагностике и оценке эффективности лекарственных препаратов у больных с заболеваниями пищевода и желудка. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(6):55-68 [Trukhmanov AS, Storonova OA, Ivashkin VT. Clinical impact of 24-hour pH-metry in esophageal and stomach diseases diagnostics and pharmacological drugs efficacy testing. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(6):55-68 (in Russian)]. doi: 10.22416/1382-4376-2016-26-6-55-68
- Jonasson C, Wernersson B, Hoff DA, Hatlebakk JG. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;37(5):564-72. doi: 10.1111/apt.12204
- Gawron AJ, Feinglass J, Pandolfino JE, et al. Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006–2010). Gastroenterol Res Pract. 2015;2015:689531. doi: 10.1155/2015/689531
- Zerbib F, Roman S, Bruley Des Varannes S, et al; Groupe Français De Neuro-Gastroentérologie. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol Hepatol. 2013;11(4):366-72. doi: 10.1016/j.cgh.2012.10.041
- Ukwueze SE, Ogbokor M, Ezealisiji KM. Quality Assessment of Different Brands of Rabeprazole Tablets Marketed In Some Nigerian Cities. J Pharm Chem Biol Sci. 2017;5(4):345-53.
Supplementary files
